- Home
- HBAN vs BIIB Comparison
HBAN vs BIIB Comparison
Compare HBAN & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBAN
- BIIB
- Stock Information
- Founded
- HBAN 1866
- BIIB 1978
- Country
- HBAN United States
- BIIB United States
- Employees
- HBAN N/A
- BIIB N/A
- Industry
- HBAN Major Banks
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- HBAN Finance
- BIIB Health Care
- Exchange
- HBAN Nasdaq
- BIIB Nasdaq
- Market Cap
- HBAN 25.6B
- BIIB 25.1B
- IPO Year
- HBAN N/A
- BIIB 1991
- Fundamental
- Price
- HBAN $17.61
- BIIB $157.78
- Analyst Decision
- HBAN Buy
- BIIB Buy
- Analyst Count
- HBAN 18
- BIIB 25
- Target Price
- HBAN $17.19
- BIIB $258.57
- AVG Volume (30 Days)
- HBAN 12.8M
- BIIB 1.6M
- Earning Date
- HBAN 01-17-2025
- BIIB 10-30-2024
- Dividend Yield
- HBAN 3.52%
- BIIB N/A
- EPS Growth
- HBAN N/A
- BIIB 10.05
- EPS
- HBAN 1.03
- BIIB 11.06
- Revenue
- HBAN $6,690,000,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- HBAN N/A
- BIIB N/A
- Revenue Next Year
- HBAN $5.31
- BIIB N/A
- P/E Ratio
- HBAN $17.09
- BIIB $14.26
- Revenue Growth
- HBAN N/A
- BIIB N/A
- 52 Week Low
- HBAN $11.78
- BIIB $153.62
- 52 Week High
- HBAN $18.45
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- HBAN 58.24
- BIIB 33.43
- Support Level
- HBAN $17.42
- BIIB $158.44
- Resistance Level
- HBAN $17.96
- BIIB $162.62
- Average True Range (ATR)
- HBAN 0.32
- BIIB 3.19
- MACD
- HBAN -0.12
- BIIB 0.90
- Stochastic Oscillator
- HBAN 22.94
- BIIB 35.65
About HBAN Huntington Bancshares Incorporated
Huntington is a regional us bank with around $200 billion in assets (as of September 2024) and has a large presence, particularly in the Midwestern market. It offers a full suite of consumer deposit and lending services, along with commercial services focused on payments, investment management, capital markets, equipment financing, treasury management, and other common banking services.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.